Introduction
Cell suicide processes play a significant role in cancer suppression and therapeutic response. Of particular interest are processes that are connected specially to the death decisions made by cells harboring preneoplastic or neoplastic lesions. Losses in suicide processes that are germane to cancer pathophysiology would be expected to promote cancer progression and to blunt therapeutic responses to cancer drugs. While great progress has been made in identifying the basic mechanisms of apoptosis, it remains unclear in many cases exactly how these mechanisms impact cancer and therapy as they occur in humans. There has also been little progress is uncovering apoptotic mechanisms that are specially associated with cancer pathophysiology (that is, mechanisms that are germane to cancer as a disease, rather than to apoptosis generally). Such processes are of great interest, as they may help distinguish cancers that will become clinically troublesome and help improve treatment for those that do so.
We have investigated the proapoptotic properties of farnesyltransferase inhibitors (FTIs) as a way to gain novel insight into cancer cell suicide processes. FTIs are a class of experimental chemotherapeutic agents that potently trigger p53-independent apoptosis in transformed rodent cells, but that often have little to no effect on the survival of nontransformed cells (reviewed in Prendergast, 2000; Cox, 2001) . Preclinical tests have established a variety of antineoplastic properties of FTIs in various model systems, including proapoptotic effects; this class of drugs has moved to clinical testing, with some promising results emerging recently in breast cancer trials.
FTIs were developed originally as a strategy to attack the farnesylation requirement of oncogenic Ras in human cancers. Recent work, however, has made it clear that FTI responsiveness is based upon factors beyond Ras targeting. Our laboratory has developed a model for the FTI mechanism of action that features the small GTPase RhoB as a critical gain-of-function target of these drugs (Prendergast, 2001) . A genetic proof of the crucial and transformation-selective role for RhoB in apoptosis by FTI and other agents used in the clinic to attack cancer cells has been demonstrated recently using a knockout mouse model system (Liu et al., , 2001a . Identifying genes that act downstream of RhoB may reveal further insights into this novel cell death mechanism. Loss of such genes would be expected to promote cancer progression and to limit the action of therapeutic agents that exploit the heightened sensitivity of most cancer cells to cell death. This issue is particularly germane to FTI, where clinical studies have not recapitulated the promising results of preclinical testing, perhaps due to secondary events that occur in frank clinical cancers but are absent in model systems.
In this study, we have identified a role for the tumor suppressor gene Bin1 in the transformation-selective apoptotic program triggered by FTI. Bin1 is an adapterencoding gene that was initially identified via c-Myc interaction (Sakamuro et al., 1996) . Bin1 can induce cell death in human cancer cells and in c-Myc-transformed primary cells (DuHadaway et al., 2001; Elliott et al., 2000) . However, the breadth of studies on Bin1 to date suggest a much more complex and integrative signaling function which extends beyond the Myc network. The two ubiquitous Bin1 adapter proteins generated by alternate splicing localize to the nuclear and/or cytosolic compartments of the cell. Bin1 splice isoforms, some of which are alternately termed amphiphysin II isoforms, have been suggested to control actin organization, endocytosis, and transcription (Wigge and McMahon, 1998; Prendergast, 1999) . Roles in myoblast differentiation and membrane deformation related to cytosolic localization have been suggested (Wechsler-Reya et al., 1998; Lee et al., 2002) . Notably, isoforms of Bin1 that localize to the nucleus can suppress transformation by Myc and other oncogenes, and trigger p53-independent apoptosis in human breast cancers, prostate cancers, melanomas, astrocytomas, and neuroblastomas where expression of the endogenous Bin1 gene is frequently lost, altered, or inactivated (Sakamuro et al., 1996; Elliott et al., 1999 Elliott et al., , 2000 Galderisi et al., 1999; Ge et al., 1999 Ge et al., , 2000a Hogarty et al., 2000; Huang et al., 2000) . A recent study of the Bin1 homolog in fission yeast, hob1+, identifies an evolutionarily conserved requirement in stress-signaling and cell cycle control (Routhier et al., 2003) . We have proposed that Bin1 adapter proteins act as 'bridging integrators' that link nuclear and cytosolic stress-signaling pathways in cells, perhaps coupling nuclear regulators such as c-Myc to actin control or vesicle dynamics (Prendergast, 1999) . Here we show that the role of Bin1 in programmed cell death is contingent on transformation-associated stress. Our results reveal genetic interactions between RhoB and Bin1 in the regulation of cell death in transformed cells.
This finding bears on the functions of BAR adapter proteins, which are poorly understood, by supporting the idea that these proteins function in signal transduction. One clinical implication of our work is the potential explanation it offers for why FTI susceptibility is limited in human cancers where Bin1 expression is frequently lost, such as breast cancers.
Materials and methods

Tissue culture
The generation and characterization of Bin1 nullizygous animals will be described elsewhere. The heads, limbs, and internal organs were removed from E13.5 embryos from pregnant mice. Carcasses were individually minced in DMEM and trypsinized 20 min at 371C. Fetal bovine serum (FBS) was added to stop the trypsin and the cell suspension was seeded into 25 cm 2 flasks containing DMEM and 10% calf serum. A portion of this dispersed tissue was used for genotypic analysis. Early passage fibroblasts were derived similarly from embryos from p53 -/-mice (a gift of A Levine). Embyro fibroblasts were transformed at passage 2-3 by transfection with 10 mg each pT22 (mutant human H-Ras vector) and p1A/neo (adenovirus E1A) or pCMVneo Tag (SV40 T antigen) (Prendergast et al., 1991), essentially as described previously . p1A/neo contains a fragment of the adenovirus genome that expresses the 13S, 12S, and 9S E1A polypeptides.
In some experiments, we also examined the response of a mutant H-Ras-transformed mouse embryo fibroblast (MEF) cell clone that arose from a focus but that did not express E1A (presumably established by spontaneous immortalization). Cells were passaged at a 1 : 5 ratio the day after transfection and transformed cell foci were cloned and expanded into E1A+Ras (ER)-or T+Ras (TR)-transformed cell lines 12-14 days later. The status of Ras farnesylation in ER and TR cells was documented by a Western mobility shift assay that has been described . A derivative of ER +/+ cells that overexpressed Bcl-2 was generated by transfection of a human Bcl-2 vector (Sakamuro et al., 1995) . Transgene expression was confirmed by Western analysis with a Bcl-2 antibody (Santa Cruz Biochemicals).
Cell assays
Cell morphology was documented by photography after 40 h treatment with 10 mm FTI L-744,832 or DMSO carrier , or after 24 h treatment with 10 ng/ml TNF-a (Alexis) with or without 2.5 mg/ml cycloheximide (Sigma). Anchorage-independent cell proliferation was monitored in soft agar culture as described previously. The phosphotidylinositol 3 0 kinase (PI3 0 K) inhibitor LY294002 (Calbiochem) was used at 10 mm for some apoptosis experiments. For flow cytometry, 5 Â 10 5 cells were seeded onto 60 mm dishes and treated 16 h later with FTI L-744-832 or vehicle in DMEM containing 0.1% calf serum. After 24 h cells were harvested by trypsinization, washed once with PBS, fixed in 70% ethanol, and stained in PBS containing 5 mg/ml propidium iodide, 10 mg/ml RNase A, and 0.1% glucose. Flow cytometry was performed essentially as described previously , using a FACScan cell analyzer and CellQuest software (Becton-Dickinson). The proportion of cells in the sub-G1 phase DNA fraction, which exhibit DNA degradation, has been demonstrated to be correlated with an apoptotic phenotype in this system (Liu et al., , 2001a .
Gene expression and activity assays
For Northern analysis, total cytoplasmic RNA was isolated from +/+ and -/-MEFs and examined essentially as described (Prendergast and Cole, 1989) . Blots were hybridized with a 32 P-labeled probe generated from a mouse Bin1 cDNA probe using standard methods. Apoptosis was confirmed in cell extracts by Western analysis of the caspase-3 substrate PARP (Chemicon).
Actin immunofluorescence
Cells were seeded onto coverslips in 24-well dishes and treated the next day for 40 h with 10 mm L-744-832 or an equivalent volume of vehicle. Cells were fixed and stained with fluorescein-phalloidin (Molecular Probes) as described previously (Prendergast et al., 1994) before analysis and photographed on a Nikon immunofluorescence microscope.
Tumor xenograft assay ER cells were tested for tumorigenic potential in 6-8 week old scid mice (Fox Chase CB-17 scid mouse strain established at The Wistar Institute by D Bosma). Mice were injected subcutaneously on the upper thigh of different legs of the same animal with 10 6 +/+ or -/-cells suspended in 200 ml of DMEM. Palpable tumors appeared at the injection site within 1 week and visible nodules of >0.5 cm appeared within 2 weeks. For FTI experiments, when the tumor reached B50-100 mm 3 , mice were dosed once daily as described by intraperitoneal injection with FTI L-744,832 (40 mpk/day) or 30% DMSO carrier in 0.2 ml total volume. Tumor volumes were calculated using the formula width 2 Â length Â 0.52.
Results
Farnesyltransferase is susceptible to inhibition in cells lacking Bin1
Experiments in E1A+Ras-transformed cells have established that FTIs must elicit a gain-of-function in RhoB to activate apoptosis . However, the elements required downstream or in parallel to RhoB are undefined. p53 mediates many cell suicide events, but p53 is largely dispensable for FTI-induced apoptosis (Lebowitz et al., 1997) . We therefore explored other tumor suppressor genes that have been implicated in cell death control. Based on previous studies in our laboratory we speculated that FTI-induced apoptosis might involve Bin1, a tumor suppressor gene identified by virtue of its interaction with c-Myc (Sakamuro et al., 1996) and implicated recently in programmed cell death processes in human tumor cells and in Myc-transformed primary cells (Elliott et al., 2000; DuHadaway et al., 2001) . To test this hypothesis, we employed a model cell system using embryo fibroblasts that were isolated from mice in which the Bin1 gene had been targeted for deletion by homologous recombination. Generation and characterization of these mice, which lack expression of all the splice isoforms of the Bin1 gene, is described elsewhere (Muller et al., manuscript submitted). MEFs were isolated from E13.5 embryos that were wild-type (+/+) or homozygous null (-/-) for the Bin1 gene. Northern analysis confirmed expression of Bin1 messages in +/+ but not in -/-MEFs, consistent with embryo genotypes (Figure 1 ). Wild-type MEFs express the two ubiquitous splice isoforms of Bin1; other splice isoforms expressed specifically in the central nervous system or skeletal muscle are undetectable in these cells (Muller et al., manuscript submitted) . FTIs only activate apoptosis in transformed cells (Lebowitz et al., 1997; Suzuki et al., 1998) , so primary MEFs were cotransformed by adenovirus E1A plus mutant H-Ras. Nullizygous MEFs were susceptible to focus formation and cell lines derived from individual foci readily formed colonies in soft agar (data not shown). E1A+Ras-transformed cells are termed ER cells below and the +/+ or -/-genotype noted refers to Bin1 unless otherwise indicated. ER cell transgene expression and transformed phenotype were confirmed by Western analysis and tumor formation in immunocompromised scid mice, respectively (data not shown). We concluded that MEFs lacking Bin1 are susceptible to oncogene transformation.
Mutant Ras must be farnesylated to cooperate with E1A in primary cell transformation; so Bin1 deletion did not compromise Ras farnesylation in cells. To establish that Bin1 deletion did not affect the susceptibility of endogenous FT to suppression by FTI, for example, by promoting drug efflux or turnover, we compared the Figure 1 Northern analysis of MEF RNA. Total cytoplasmic RNA isolated from +/+ or -/-primary MEFs were fractionated on Northern gels that were blotted and hybridized to a 32P-labeled Bin1 cDNA probe. The bottom panel presents a photograph of the ethidium bromide-stained gel as a control for RNA loading farnesylation status of H-Ras in drug-treated cells. Following 24 h treatment with FTI L-744,832 or vehicle only, ER cells were lysed and processed for Western analysis with anti-Ras antibody Y13-259, as described . H-Ras farnesylation was blocked with similar efficiency in +/+ and -/-cells, as illustrated by a similar shift in gel mobility that is diagnostic for inhibition of farnesylation (Figure 2) . We concluded that loss of Bin1 does not affect FT activity or susceptibility to inhibition by FTIs.
Bin1 is dispensable for morphological reversion, actin stress fiber formation, and growth inhibition by FTIs Following FTI treatment, Ras-transformed cells undergo a rapid shift to a flat morphology that is associated with robust actin stress fiber formation (Prendergast et al., 1994) . We have established that a gain of function alteration of RhoB is sufficient and necessary for these drug responses in MEFs transformed by E1A and Ras . Bin1 adapter proteins are not farnesylated and Bin1 deletion did not affect the ability of FTIs to elicit the gain-of-function in RhoB, as expected (data not shown). To determine whether Bin1 is essential to various facets of the FTI response, we first compared the morphology and actin stress fiber networks of ER cells treated with FTI. Actin stress fibers were monitored by immunofluorescence microscopy of cells stained with fluorescein-conjugated phalloidin, which binds specifically to filamentous actin. Untreated ER -/-cells displayed a more spindle and rounded morphology and reduced actin ruffles. Nevertheless, these cells exhibited a robust reversion and actin stress fiber response to FTIs in the same manner as ER +/+ cells (Figure 3) . Thus, unlike RhoB , Bin1 was not required for FTI-induced actin reorganization. FTIs also inhibit the proliferation of Rastransformed cells (reviewed in Prendergast, 2000) . A comparison of the proliferation of ER cells in soft agar culture showed that FTIs inhibited colony formation of ER +/+ and ER -/-with the same efficiency ( Figure 4) . Thus, Bin1 was also not required for FTI-induced growth inhibition. We concluded that Bin1 was dispensable for the RhoB-dependent effects of FTIs on ER cell morphology, cytoskeletal actin organization, and anchorage-independent growth.
Bin1 is crucial for apoptosis by FTI
When Ras-transformed cells are deprived of serum growth factors or substratum adhesion, they undergo apoptosis instead of growth inhibition in response to FTI treatment (Lebowitz et al., 1997; Suzuki et al., 1998; Du et al., 1999b; Liu et al., 2000) . Which response predominates is determined by the status of the PI3 0 KAkt pathway (Du et al., 1999b) . Insufficient PI3 0 K-Akt activity makes cells susceptible to apoptosis. This condition is generated in transformed cells by serum deprival, substratum deprival, or PI3 0 K inhibition. Under such conditions, RhoB is crucial to engage apoptosis . To test whether Bin1 is also crucial, we compared the apoptotic response of the (Mangues et al., 1998) , except that antiRas monoclonal antibody Y13-259 was used to hybridize the Western blot. The decrease in the apparent gel mobility of Ras is diagnostic for loss of farnesylation and hence inhibition of farnesyltransferase ER +/+ cells underwent massive apoptosis when exposed to 10 mm FTI under suboptimal serum conditions, as observed previously , with detached, rounded cells appearing within 16-24 h of drug treatment. Flow cytometry indicated an Beightfold increase in the sub-G1 phase population of cells, a diagnostic indicator for FTI-induced apoptosis in this system (Liu et al., , 2001a . In contrast, ER -/-cells underwent morphological reversion to a flat phenotype but did not display increased detachment or rounding. Longer incubation times or higher drug concentrations did not elicit cell demise, arguing that Bin1 did not merely promote drug response kinetics (data not shown). Flow cytometry confirmed growth inhibition, revealing a reduction of S and G2 phase cells and an increase of G1 phase cells. However, no substantial increase in sub-G1 phase cells occurred. Caspase-3 activation and PARP cleavage occurs during FTIinduced apoptosis (Suzuki et al., 1998; Du et al., 1999b) . Characteristic cleavage of PARP occurred in ER +/+ cells, beginning at 4-8 h after FTI treatment, whereas PARP was not cleaved in ER À/À cells (Figure 5b ). This response was dependent upon the transformed status of the cell, rather than the presence of E1A, insofar as a similar resistance to FTI-induced apoptosis was displayed by a variant Ras-transformed MEF cell line that arose from a rare focus which did not express E1A (data not shown). Furthermore, the death resistance phenotype was not insurmountable, as treatment with TNF-a plus cycloheximide triggered apoptosis similarly in primary MEFs or E1A+Ras-transformed MEFs that were either wild-type or nullizygous for Bin1 (data not shown).
To further substantiate the death resistance phenotype of ER -/-cells, we compared the response of ER +/+ cells engineered to overexpress Bcl-2. Western analysis confirmed transgene expression in ER +/+ Bcl-2 cells (Figure 5c, inset) . The appearance of sub-G1 phase cells was suppressed B2.5-fold following FTI treatment, as measured by flow cytometry, relative to vector control ER +/+ cells (Figure 5c ). The less robust suppression conferred by Bcl-2 in ER +/+ cells supports a different basis for the FTI-resistant phenotype of ER -/-cells. To corroborate these observations, we determined whether ER -/-cells were resistant to apoptosis induced by FTI in the presence of serum plus the PI3 0 K inhibitor LY294002 (Du et al., 1999b) . As observed previously, ER +/+ cells underwent apoptosis when treated 24 h with 10 mm FTI plus 10 mm LY294002 (Figure 6 ). By itself LY294002 shifted the morphology of ER +/+ cells but did not substantially affect their viability, as quantitated by the proportion of sub-G1 phase cells measured by flow cytometry. In contrast, LY294002 did not cooperate with FTI to activate apoptosis in ER -/-cells ( Figure 6 ). Interestingly, Bin1 deletion also eliminated the morphological shift caused by LY294002 in the absence of FTI, suggesting that Bin1 may mediate certain PI3 0 Kdependent effects on cell shape. In summary, these observations supported the conclusion that Bin1 is crucial for apoptosis by FTIs.
p53 deletion does not replicate the apoptotic defect of Bin1 deletion
Although there is evidence that p53 is largely dispensable for the antiproliferative and proapoptotic activities of FTIs (Sepp-Lorenzino et al., 1995; Lebowitz et al., 1997; Barrington et al., 1998) , we wished to explicitly address the possibility that p53 deletion could phenocopy the death resistance displayed by ER -/-cells. Toward this end, p53 nullizygous MEFs were transformed by E1A plus mutant Ras, generating ER p53 -/-cells for examination (Figure 7) . In response to FTI treatment, ER p53 -/-cells underwent morphological reversion, stress fiber induction, and growth inhibition. In suboptimal serum conditions, ER p53 -/-cells also underwent apoptosis (Figure 7 , bottom panels). The efficiency of the response as quantitated by flow cytometry was blunted partially relative to ER cells with intact p53. Nevertheless, the result established that p53 deletion does not abolish FTI-induced apoptosis in the same manner as Bin1 deletion.
SV40 T antigen, which inhibits p53-independent cell death induction by Bin1, inhibits apoptosis by FTI
We took a second approach to corroborate the Bin1 requirement in FTI-induced apoptosis, based on evidence that SV40 large T antigen can suppress Bin1-induced cell death in a p53-independent manner (Elliott et al., 2000) . In these experiments, MEFs were transformed by T antigen plus mutant Ras, generating TR cells for examination. Based on the evidence above, We confirmed similar susceptibility to FT inhibition in TR cells (Figure 8a ). As seen in ER cells, TR cells exhibited similar actin stress fiber and growth inhibitory responses to FTI treatment (Figures 8b and c) . In contrast, both +/+ and TR -/-cells were resistant to FTI-induced apoptosis (Figure 8d ). This result offered a second line of corroboration for the conclusion that Bin1 was required for the apoptotic response of transformed cells to FTI treatment.
Bin1 is critical for the antineoplastic response of tumor xenografts to FTI treatment
Previous work established that the apoptotic defect caused by RhoB loss compromises the response of tumor allografts to FTI treatment in vivo. Since Bin1 deletion produced a similar apoptotic defect, we compared the FTI response of ER +/+ and -/-cells grown as allografts in severe combined immunodeficient (scid) mice. Cells (10 7 ) were injected into the opposite thighs of the same animal, to control for nonspecific environmental effects, in a total of twenty mice. Palpable +/+ and -/-tumors in each animal formed within 7 days of injection. At 1 week after the allograft was initiated, mice were assigned randomly to control or drug treatment groups. The drug treatment group was dosed once daily for 16 days by intraperitoneal injection with 40 mg/kg FTI L-744,832 as described . Control mice were given vehicle carrier only. Tumor volumes were calculated from caliper measurements taken at various times during the trial. No adverse side-effects of L-744,832 administration were observed consistent with previous observations Barrington et al., 1998; Mangues et al., 1998; Liu et al., 2000) . At the end of the trial, mice were euthanized and their tumors were surgically excised for weighing and examination. ER allografts exhibited a significantly different susceptibility to FTI suppression (Figure 9 ). -/-tumors exhibited a higher apparent growth rate, but the difference with +/+ xenografts was not statistically significant. Similar to previous observations , +/+ tumors were strongly inhibited by the drug protocol and grew little relative to controls. In contrast, -/-tumors continued to grow robustly such that by the end of the experiment they were statistically similar to controls in size. The fact that -/-tumors continued to grow in FTI-treated animals implies that apoptotic capacity plays a predominant role in the in vivo response. We concluded that Bin1 is crucial to the antineoplastic response of tumor cells to FTI treatment.
Discussion
This study defines a critical role for the tumor suppressor Bin1 in the cell suicide program engaged by FTI in transformed primary mouse cells. This program is marked by its peculiar selectivity in transformed cells: most FTIs studied to date have little to no effect on the 5 cells were seeded into 60 mm dishes, treated as above, and processed as described. The proportion of cells in the sub-G1 phase DNA fraction (degraded DNA) is diagnostic for apoptosis in this cell system . The quantitation of sub-G1 phase cells is noted above the bar in the flow cytometry histograms. (b) PARP cleavage. ER cells were treated with 10 mm FTI for the times indicated and cell extracts were prepared and analysed by Western analysis with a PARP antibody. The cleaved product appears below the indicated fulllength protein. (c) Bcl-2 overexpression does not replicate the Bin1 -/-resistance phenotype. ER +/+ derivatives overexpressing human Bcl-2 (inset) were treated as in (a) viability of nontransformed mouse cells, but they are potent inducers of apoptosis in cells that are transformed by Ras and certain other oncogenes. This characteristic makes FTIs a useful probe of cell death processes that are intimately connected to the pathophysiology of neoplastically transformed cells. While FTIs have a variety of effects on transformed mouse cells, such as reversion, stress fiber induction, and growth inhibition, we demonstrated that Bin1 is required only for FTIs to trigger apoptosis. The apoptotic defect in cells lacking Bin1 is significant because the defect compromised the antitumor efficacy of FTIs in vivo. Bin1 proteins appear to act downstream or in parallel to the FTI target protein RhoB, which is sufficient and/or necessary to mediate the major features of the FTI response in the mouse, including apoptosis, via a gain-of-function mechanism (Du et al., 1999a; Du and Prendergast, 1999; Liu et al., 2000) . These findings identify Bin1 as a second element with RhoB that is part of a cell death process linked to transformed cell pathophysiology. RhoB has important functions in stress signaling (Prendergast, 2001 ) and recent genetic investigations in fission yeast support a similar role in stress signaling for Bin1 (Routhier et al., 2003) . Thus, the specific requirements for RhoB and Bin1 in FTIinduced apoptosis may reflect broader roles for these genes in a unique stress signaling process. Preliminary experiments using TNF-a, another factor that selectively targets the survival of transformed mouse cells, support the conclusion that Bin1 has a function in apoptosis that is contingent upon a transformation-related stress. Loss of Bin1 compromised the ability of TNF to trigger apoptosis in ER cells, but it did not affect the ability of TNF plus cycloheximide to kill primary cells or ER -/-cells. In this cell system, the death defect compromised mitochondrial release of cytochrome c and activation of caspases-9 and -3 in a manner that was associated with dysfunctional control of NFkB, at a level beyond IkB regulation (unpublished observations). Taken together, these observations argue that Bin1 is needed to mediate Figure 6 Bin1 deletion abolishes apoptosis by FTI-II. Morphology (top panels). ER cells were photographed after 24 h treatment with DMEM containing 10% FBS plus DMSO vehicle or 10 mm FTI in the presence or absence of 10 mm L294002. Flow cytometry (bottom panels). Cells were treated as above and processed as before. The quantitation of sub-G1 phase cells is noted above the bar in the flow cytometry traces the death sensitization caused by neoplastic transformation in certain settings.
During cancer progression, a strong selection is expected against transformation-associated 'death penalties' that limit cell survival. Therefore, the functional status of genes that mediate such processes would be expected to have a significant impact on cancer progression. Such genes would also be expected to impact therapeutic responses, in cases where the 'therapeutic window' is based upon heightened death sensitivity. The results of the present study suggest that Bin1 status may be an important determinant of apoptotic susceptibility to FTI. Notably, losses of Bin1 expression occur frequently in advanced breast and prostate cancers (Ge et al., 2000a, b) and Bin1 is frequently inactivated by missplicing during the progression of malignant melanoma (Ge et al., 1999) . These observations may be relevant to the interpretation of ongoing FTI clinical trials which aim at assessing and interpreting efficacy in various cancers, including the ones mentioned above.
Bin1 has been implicated in a variety of processes but its function has yet to clearly emerge. This gene encodes several alternately spliced adapter proteins, the first of which was identified by virtue of its functional interaction with c-Myc (Sakamuro et al., 1996; Elliott et al., 1999) . Recent studies support a role for Bin1 in death signaling in c-Myc-transformed cells and in human cancer cells (Elliott et al., 2000; DuHadaway et al., 2001) , where Bin1 is frequently silenced or inactivated by missplicing (Ge et al., 1999 (Ge et al., , 2000a . In these studies, Bin1 was implicated in cell death in malignant or transformed primary cells, but not in nonmalignant or nontransformed cells. The present study supports and extends the earlier work, by using a knockout system that can offer more robust and direct support of a role for Bin1 in cell death signaling.
While initial studies focused on proposed connections between Bin1 and c-Myc, the breadth of work to date on the Bin1 gene reveals a more complex and integrative signaling function that extends beyond the Myc network. Bin1 proteins are members of the BAR family of adapter proteins, including the budding yeast Rvs proteins and the mammalian amphiphysin protein, which have been implicated in actin regulation, endocytosis, and nuclear processes (Wigge and McMahon, 1998; Colwill et al., 1999; Bon et al., 2000) . Budding yeast studies in particular suggest an important role for the actin cytoskeleton as a key site of action for BAR adapter proteins (Breton and Aigle, 1998; Balguerie et al., 1999; Colwill et al., 1999) . However, Bin1 appears to have functions that differ from and/or extend beyond those defined for amphiphysin and the Rvs proteins, as suggested, for example, by (i) the nuclear localization of certain Bin1 isoforms and their functional interaction with nuclear Myc and Abl proteins (Kadlec and Pendergast, 1997; Wechsler-Reya et al., 1997; Elliott et al., 1999) , (ii) the lack of endocytosis defects in Bin1 -/-cells (A Muller et al., manuscript submitted), and (iii) the ability of Bin1 to complement defects in stressinduced cell cycle control that are generated in fission yeast following deletion of the Bin1 homolog hob1+ (Routhier et al., 2003) . In summary, Bin1 adapter proteins have complex signaling functions in animal cells, perhaps related to stress signaling, that have yet to be fully understood.
Other connections between RhoB and Bin1 proteins can be drawn in support of their involvement in a common signaling process. Bin1 proteins lack evident Rho-interaction motifs and do not appear to associate with Rho proteins. However, a Rho guanine nucleotide exchange factor (RhoGEF) was recently identified as a Figure 7 p53 deletion does not replicate the Bin1 defect. ER p53 -/-cells were exposed to 10 mm FTI or DMSO vehicle in DMEM containing 10% FBS (morph, actin, growth panels). Morphology was documented by photography 40 h after FTI treatment. Actin and cell growth in soft agar culture were assayed as above. Apoptotic response was assessed in DMEM containing 0.1% FBS. After culturing 24 h in the presence of 10 mm FTI or DMSO vehicle, cells were photographed and the harvested and processed for flow cytometry as above. The quantitation of sub-G1 phase cells is noted above the bar in the flow cytometry traces Bin1-binding protein in our laboratory, and several other members of the human BAR adapter family actually include RhoGEF and RhoGAP domains as part of their structure (AM and GCP, unpublished observations). Moreover, some of these genes include membrane-targeting sequences such as pX and PH domains that in some cases have been linked to actinbased systems or vesicle dynamics. Neuronal isoforms of Bin1, also referred to as amphiphysin II, are found in specialized endocytotic complexes that function in synaptic vesicle endocytosis (Wigge and McMahon, 1998) . While studies in Bin1 knockout mice have failed to identify an essential role for this gene in endocytotic processes (Muller et al., manuscript submitted), the presence of at least some Bin1 isoforms in endocytotic complexes suggests some role in those complexes, perhaps to integrate stress signals. Genetic analysis of RVS167, the ortholog of Bin1 in budding yeast, points to direct interactions with actin (Bauer et al., 1993; Amberg et al., 1995; Breton and Aigle, 1998; Balguerie et al., 1999) , including a role in coordinating cytoskeletal and cell cycle responses (Lee et al., 1998) . Recent work on hob1+, the homolog of Bin1 in fission yeast, suggests that the function of Bin1 may have diverged to some extent during evolution. Fission yeast cells lacking hob1+ do not display actin cytoskeletal or endocytotic defects, like budding yeast cells lacking 7 ER +/+ or -/-cells were injected subcutaneously into opposite thighs of a single scid mouse (total of 20 mice). Mice were assigned randomly to drug treatment or control groups and 1 wk later dosed daily for 16 days by intraperitoneal injection with FTI (40 mg/kg) or vehicle carrier. One animal in the treatment group died as a result of an errant injection. Tumor size was measured by caliper and tumor volume was computed as described in the Materials and Methods. The data represent the average and standard mean error of the tumor volume as computed at the times indicated RVS167, but instead display defects in stress responses triggered by starvation or DNA damage (Routhier et al., 2003) .
The likely intersections of Bin1 with stress signaling, actin, and membrane dynamics are intriguing in light of the same intersections made by RhoB, which is localized in cytosolic membranes but also to the nucleus and/or nuclear membrane (Adamson et al., 1992; Lebowitz et al., 1995; Zalcman et al., 1995; Lebowitz and Prendergast, 1998; Michaelson et al., 2001 ) (L Benjamin, pers. comm.). In the endosomal compartment, RhoB regulates intracellular receptor trafficking through interactions with its effector kinase PRK (Mellor et al., 1998; Gampel et al., 1999) , which has also been implicated in apoptosis (Cryns et al., 1997; Takahashi et al., 1998; Koh et al., 2000) . Given the possibility of an effector role for Bin1 in the FTI cell suicide program, it is tempting to speculate that Bin1 may be regulated or modified at some level by Rho signals that are actinbased but directed to or from the nucleus. Regulation by PI3 0 K signaling may also be germane, given that Bin1 deletion compromises the morphological as well as the proapoptotic effects of the PI3 0 K inhibitor LY294002 in the transformed MEF system. This study offers a biological foundation for investigations of the genetic interactions between RhoB and Bin1 and of a unique death-signaling mechanism that links these genes to transformed cell stress and cancer pathophysiology.
